Kodiak Sciences announces GLOW2 Phase 3 DR trial meets primary endpoint; ≥2-step DRSS improvement climbs to 62.5% on Zenkuda vs 3.3% on sham

Reuters03-26 18:02

Kodiak Sciences announces GLOW2 Phase 3 DR trial meets primary endpoint; ≥2-step DRSS improvement climbs to 62.5% on Zenkuda vs 3.3% on sham

Kodiak reported positive topline results from GLOW2, a Phase 3 study evaluating Zenkuda (tarcocimab tedromer) versus sham in diabetic retinopathy.
The primary endpoint was met, with 62.5% of Zenkuda-treated patients achieving a ≥2-step improvement in DRSS at Week 48 versus 3.3% with sham (p<0.0001).
In a key secondary endpoint, the rate of prespecified sight-threatening complications through Week 48 was 2.4% with Zenkuda versus 15.8% with sham (p=0.0001).
Safety findings included a 0% intraocular inflammation rate and a 2.3% cataract adverse event rate (vs 1.6% with sham).
Full end-of-study results are planned to be presented at an upcoming congress by Charles Wykoff.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kodiak Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF19595) on March 26, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622285546?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 18:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622285546","market":"nz","top_or_hot":-1,"title":"Kodiak Sciences announces GLOW2 Phase 3 DR trial meets primary endpoint; ≥2-step DRSS improvement climbs to 62.5% on Zenkuda vs 3.3% on sham","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Kodiak Sciences announces GLOW2 Phase 3 DR trial meets primary endpoint; ≥2-step DRSS improvement climbs to 62.5% on Zenkuda vs 3.3% on sham\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Kodiak reported positive topline results from GLOW2, a Phase 3 study evaluating Zenkuda (tarcocimab tedromer) versus sham in diabetic retinopathy.\n        </li>\n<li>\n          The primary endpoint was met, with 62.5% of Zenkuda-treated patients achieving a ≥2-step improvement in DRSS at Week 48 versus 3.3% with sham (p&lt;0.0001).\n        </li>\n<li>\n          In a key secondary endpoint, the rate of prespecified sight-threatening complications through Week 48 was 2.4% with Zenkuda versus 15.8% with sham (p=0.0001).\n        </li>\n<li>\n          Safety findings included a 0% intraocular inflammation rate and a 2.3% cataract adverse event rate (vs 1.6% with sham).\n        </li>\n<li>\n          Full end-of-study results are planned to be presented at an upcoming congress by Charles Wykoff.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/KOD\">Kodiak Sciences Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: SF19595) on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kodiak Sciences announces GLOW2 Phase 3 DR trial meets primary endpoint; ≥2-step DRSS improvement climbs to 62.5% on Zenkuda vs 3.3% on sham</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKodiak Sciences announces GLOW2 Phase 3 DR trial meets primary endpoint; ≥2-step DRSS improvement climbs to 62.5% on Zenkuda vs 3.3% on sham\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-26 18:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Kodiak Sciences announces GLOW2 Phase 3 DR trial meets primary endpoint; ≥2-step DRSS improvement climbs to 62.5% on Zenkuda vs 3.3% on sham\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Kodiak reported positive topline results from GLOW2, a Phase 3 study evaluating Zenkuda (tarcocimab tedromer) versus sham in diabetic retinopathy.\n        </li>\n<li>\n          The primary endpoint was met, with 62.5% of Zenkuda-treated patients achieving a ≥2-step improvement in DRSS at Week 48 versus 3.3% with sham (p&lt;0.0001).\n        </li>\n<li>\n          In a key secondary endpoint, the rate of prespecified sight-threatening complications through Week 48 was 2.4% with Zenkuda versus 15.8% with sham (p=0.0001).\n        </li>\n<li>\n          Safety findings included a 0% intraocular inflammation rate and a 2.3% cataract adverse event rate (vs 1.6% with sham).\n        </li>\n<li>\n          Full end-of-study results are planned to be presented at an upcoming congress by Charles Wykoff.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/KOD\">Kodiak Sciences Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: SF19595) on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KOD","symbol_name":"Kodiak Sciences Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL298zY8:1","article_id":"2622285546","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622285546","pubTimestamp":1774519369,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Kodiak Sciences announces GLOW2 Phase 3 DR trial meets primary endpoint; ≥2-step DRSS improvement climbs to 62.5% on Zenkuda vs 3.3% on sham. Kodiak reported positive topline results from GLOW2, a Phase 3 study evaluating Zenkuda  versus sham in diabetic retinopathy.The primary endpoint was met, with 62.5% of Zenkuda-treated patients achieving a ≥2-step improvement in DRSS at Week 48 versus 3.3% with sham .In a key secondary endpoint, the rate of prespecified sight-threatening complications through Week 48 was 2.4% with Zenkuda versus 15.8% with sham .Safety findings included a 0% intraocular inflammation rate and a 2.3% cataract adverse event rate .Full end-of-study results are planned to be presented at an upcoming congress by Charles Wykoff.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not b","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KOD":"Kodiak Sciences Inc.","BK4505":"高瓴资本持仓","BK4139":"生物科技"},"translate_title":"Kodiak Sciences宣布GLOW2 3期DR试验达到主要终点；Zenkuda组DRSS改善≥2步攀升至62.5%，而sham组为3.3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KOD":0.9},"content_text":"Kodiak Sciences announces GLOW2 Phase 3 DR trial meets primary endpoint; ≥2-step DRSS improvement climbs to 62.5% on Zenkuda vs 3.3% on sham\n    \n\n\n          Kodiak reported positive topline results from GLOW2, a Phase 3 study evaluating Zenkuda (tarcocimab tedromer) versus sham in diabetic retinopathy.\n        \n\n          The primary endpoint was met, with 62.5% of Zenkuda-treated patients achieving a ≥2-step improvement in DRSS at Week 48 versus 3.3% with sham (p<0.0001).\n        \n\n          In a key secondary endpoint, the rate of prespecified sight-threatening complications through Week 48 was 2.4% with Zenkuda versus 15.8% with sham (p=0.0001).\n        \n\n          Safety findings included a 0% intraocular inflammation rate and a 2.3% cataract adverse event rate (vs 1.6% with sham).\n        \n\n          Full end-of-study results are planned to be presented at an upcoming congress by Charles Wykoff.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kodiak Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF19595) on March 26, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622285546","isCrawlerRequest":true}